AndroGel Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

Does AndroGel Directly Interact with Anesthetic Drugs?

No published randomized controlled trial has demonstrated a direct pharmacokinetic interaction between transdermal testosterone gel and standard volatile anesthetics (sevoflurane, desflurane, isoflurane) or IV induction agents (propofol, ketamine, etomidate). That absence of evidence is not the same as confirmed safety. The clinical risk profile of AndroGel in the perioperative window comes almost entirely from downstream hematologic and coagulation effects rather than from any receptor-level competition with anesthetic molecules.

What the FDA Label Says

The AndroGel prescribing information approved by the FDA lists venous thromboembolism (VTE), polycythemia, and potentiation of oral anticoagulants as the most clinically significant risks during testosterone therapy [1]. None of these risks disappear on the day of surgery. A patient who enters the operating room with a hematocrit of 56% and is simultaneously taking warfarin faces a compounded perioperative hazard that anesthesia teams must account for in their preoperative assessment.

Pharmacokinetics Relevant to Surgery

Transdermal testosterone reaches steady-state serum levels within 24 to 48 hours of the first dose and returns to below-normal levels within approximately 72 to 96 hours after the last application [1]. That relatively short offset window is why a 5-to-7-day hold before elective procedures gives meaningful physiologic buffer without risking symptomatic hypogonadism in most patients [2].

Polycythemia: The Primary Anesthetic Hazard

Polycythemia is the most clinically relevant hematologic effect of testosterone therapy in the surgical context. The FDA-approved label for AndroGel explicitly states that hematocrit should be checked at 3 to 6 months after starting therapy and annually thereafter, with dose reduction or discontinuation if hematocrit exceeds 54% [1].

How Common Is Polycythemia on TRT?

A 2010 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=51 trials, 4,351 participants) found that testosterone therapy increased hematocrit by a mean of 3.18 percentage points compared with placebo, with polycythemia (hematocrit >50%) occurring in roughly 5.7% of treated men versus 0.7% of controls [3]. Transdermal formulations produced smaller increases than injectable testosterone, but the risk remains non-negligible.

Why Polycythemia Matters Under Anesthesia

Elevated red cell mass increases blood viscosity. Under general anesthesia, reduced cardiac output and positional venous stasis combine with high viscosity to raise the probability of deep vein thrombosis and pulmonary embolism. A 2019 Cochrane review on perioperative VTE prophylaxis confirmed that baseline polycythemia is an independent risk factor for postoperative thrombotic events [4]. Anesthesiologists routinely check preoperative CBC; a hematocrit above 54% in a TRT patient should trigger a conversation about delaying elective surgery.

Practical Thresholds

• Hematocrit <54%: proceed with standard VTE prophylaxis per ACCP guidelines
• Hematocrit 54 to 58%: consider therapeutic phlebotomy and a 5-to-7-day AndroGel hold before rescheduling
• Hematocrit >58%: delay elective surgery; involve hematology if secondary causes have not been excluded [3]

Anticoagulant Interactions: Warfarin and Beyond

Testosterone Potentiates Warfarin

The FDA label for AndroGel carries an explicit drug interaction warning: testosterone may increase the anticoagulant effect of warfarin, necessitating INR monitoring and dose adjustment when testosterone therapy is started, stopped, or adjusted [1]. This interaction is pharmacodynamic rather than pharmacokinetic. Testosterone appears to increase the sensitivity of clotting factor synthesis to warfarin's vitamin K antagonism [5].

A 2003 case series published in the Annals of Pharmacotherapy documented INR elevations of 1.5 to 3.4 points above target range in patients whose testosterone dose was increased without concurrent warfarin adjustment [5]. Those numbers translate directly to surgical bleeding risk.

Direct Oral Anticoagulants (DOACs)

Testosterone's interaction with DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) is less well-characterized. No large pharmacokinetic study has directly examined the combination. A 2021 FDA drug interaction database review identified no definitive contraindication, but also acknowledged insufficient data to rule out a clinically relevant effect on bleeding time when hematocrit is simultaneously elevated [6].

Preoperative INR Management

For patients on warfarin plus AndroGel, the standard perioperative recommendation is to hold AndroGel for 5 to 7 days before elective surgery, recheck INR at 48 hours pre-operatively, and apply standard bridging anticoagulation protocols as appropriate for the patient's thromboembolic risk category [7]. Restart of AndroGel post-operatively should be accompanied by INR rechecking within 5 to 7 days of resumption.

Cardiovascular Effects Relevant to Anesthetic Management

Background Cardiovascular Risk in Hypogonadal Men

Men seeking TRT often carry baseline cardiovascular risk factors including obesity, type 2 diabetes, and metabolic syndrome [8]. Those comorbidities independently affect anesthetic choice, fluid management, and postoperative monitoring requirements.

The TRAVERSE Trial

The TRAVERSE trial (N=5,204, mean follow-up 33 months) published in the New England Journal of Medicine in 2023 found that testosterone therapy in men with hypogonadism and high cardiovascular risk did not increase major adverse cardiovascular events (MACE) compared with placebo (hazard ratio 0.96, 95% CI 0.83 to 1.12) [9]. That finding somewhat reassured the field, but the trial also documented a statistically significant increase in pulmonary embolism (PE) events in the testosterone arm (hazard ratio 1.69, 95% CI 1.12 to 2.56) [9]. PE is directly relevant to any perioperative risk calculation.

Implications for Anesthetic Planning

The TRAVERSE PE signal means anesthesiologists and surgeons should classify TRT patients as being at elevated baseline thromboembolic risk even when hematocrit is within acceptable range. Pharmacologic VTE prophylaxis (low-molecular-weight heparin or unfractionated heparin) should follow the same protocols applied to other moderate-to-high VTE-risk surgical patients per ACCP Chest guidelines [10].

Drug-Drug Interactions Involving Anesthetic Adjuncts

Corticosteroids

Both corticosteroids (commonly given perioperatively for nausea or inflammation) and testosterone influence insulin sensitivity and glucose metabolism. Co-administration may cause unpredictable glycemic excursions [11]. Patients on AndroGel who receive dexamethasone or methylprednisolone intraoperatively should have blood glucose monitored every 1 to 2 hours during the procedure and in the immediate recovery period.

Opioid Analgesics

Chronic opioid use suppresses the hypothalamic-pituitary-gonadal (HPG) axis and is a common reason for secondary hypogonadism requiring TRT. In the perioperative setting, opioid-induced hypogonadism does not create a direct pharmacokinetic conflict with exogenous testosterone, but the HPG suppression may blunt any acute endogenous testosterone response to surgical stress [12]. This is an informational consideration rather than a contraindication.

Insulin and Oral Hypoglycemics

The FDA label states that testosterone may decrease blood glucose and therefore enhance the glucose-lowering effect of insulin and oral hypoglycemic agents [1]. Dose adjustments of insulin or sulfonylureas may be needed when AndroGel is started or stopped in diabetic surgical patients.

Perioperative Protocol: Hold and Restart Guidance

The table below summarizes a practical perioperative framework for patients on AndroGel. This framework synthesizes the Endocrine Society 2018 Clinical Practice Guideline on testosterone therapy [2], the FDA-approved prescribing information [1], and the TRAVERSE cardiovascular safety data [9]. No single published guideline covers all these decision points in one document. HealthRX's medical team compiled these thresholds for clinical reference, pending formal society guidance.

| Phase | Action | Rationale | |---|---|---| | 4 to 6 weeks pre-op | Check CBC, hematocrit, PSA, INR (if on warfarin) | Establish baseline; identify polycythemia or anticoagulation drift | | 5 to 7 days pre-op | Hold AndroGel | Allow hematocrit and testosterone levels to trend down before surgical stress | | 48 hours pre-op | Recheck hematocrit and INR if applicable | Confirm hematocrit <54%; adjust warfarin if INR out of range | | Day of surgery | Confirm no AndroGel application; standard VTE prophylaxis | Prevent additional viscosity increase; reduce thromboembolic risk | | Post-op day 1 to 3 | Resume VTE prophylaxis per surgical protocol | TRT patients remain at elevated PE risk in recovery | | Post-op day 5 to 7 | Restart AndroGel if hematocrit stable and hemostasis confirmed | Avoid restarting in the immediate postoperative coagulation window | | 2 weeks post-restart | Recheck hematocrit and INR (if on warfarin) | AndroGel effect on hematocrit and anticoagulation may re-emerge |

What the Endocrine Society Guideline Recommends

The Endocrine Society 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend checking hematocrit at baseline, at 3 to 6 months, and then annually. If the hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate therapy with a reduced dose" [2]. That threshold applies with equal or greater force in the perioperative period.

The same guideline advises clinicians to "evaluate cardiovascular risk carefully before initiating testosterone therapy in men with a history of cardiovascular disease" [2], a recommendation that also governs perioperative risk stratification.

Alcohol and AndroGel: A Brief Note

Patients frequently ask whether alcohol consumption affects AndroGel. Alcohol does not directly alter transdermal testosterone absorption in the short term, but chronic heavy alcohol use suppresses hepatic testosterone metabolism and may exaggerate the polycythemia-to-coagulopathy sequence described above [13]. For patients scheduled for surgery, alcohol cessation at least 48 hours pre-operatively is standard perioperative guidance regardless of TRT status.

Special Populations

Older Adults

Men over 65 have higher baseline VTE risk and are more likely to experience hematocrit elevations on TRT. A secondary analysis of the TRAVERSE trial found that the PE signal was most concentrated in men aged 65 and older [9]. Anesthesiologists should note age as an additive risk factor when evaluating TRT patients preoperatively.

Patients with Sleep Apnea

The FDA label warns that testosterone may worsen obstructive sleep apnea (OSA), which in turn raises perioperative airway risk under general anesthesia [1]. Undiagnosed OSA in a TRT patient represents a compound hazard. A preoperative STOP-BANG questionnaire score of 3 or higher should prompt polysomnography referral before elective procedures in this population [14].

Patients with Polycythemia Vera

Exogenous testosterone is contraindicated in patients with diagnosed polycythemia vera. If a patient is found to have persistent hematocrit elevation above 58% despite AndroGel discontinuation, hematology referral is mandatory before any elective surgical procedure [3].

Skin Transfer Risk in the Hospital Setting

AndroGel carries an FDA black box warning about secondary testosterone exposure through skin contact, particularly to women and children [1]. In the hospital setting, nursing and anesthesia staff should be informed if a patient applied AndroGel within 6 hours of arrival. Standard glove precautions during IV line placement and skin preparation are sufficient to prevent transfer, but the information belongs in the preoperative nursing intake form.

Summary of Key Monitoring Parameters

A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that testosterone-associated polycythemia resolves in most patients within 6 to 8 weeks of cessation, with hematocrit declining at a mean rate of approximately 1 percentage point per week after discontinuation [15]. That recovery rate supports the 5-to-7-day pre-operative hold as clinically meaningful but also underscores that high-risk patients (hematocrit >58%) may require a longer hold of 3 to 4 weeks before safe surgery.

The Endocrine Society guideline further specifies that testosterone should not be started in men with hematocrit above 48% at baseline [2], a threshold that reinforces the need for pre-operative lab work in any patient whose TRT history is unclear at time of surgical consult.